Search

Each year more than 3000 Canadians are diagnosed with brain cancers like glioblastoma multiforme or recurrent head and neck cancers, which are difficult to treat with conventional radiotherapy techniques. One of the most clinically promising treatments for these cancers is boron neutron capture therapy (BNCT). This procedure involves selectively introducing a boron delivery agent into tumor cells and irradiating them with a neutron beam, which kills the cancer cells due to the high-linear energy transfer radiation produced by the [sup.10](n,[alpha])[sup.7]Li capture reaction. The theory of BNCT has been around for a long time since 1936, but has historically been limited by poor boron delivery agents and non-optimal neutron source facilities. Although significant improvements have been made in both of these domains, it is mainly the advancements of accelerator-based neutron sources that have led to the expansion of over 20 new BNCT facilities worldwide in the past decade. Additionally in this work, particle and heavy ion transport code system simulations, in collaboration with the University of Tsukuba, were performed to examine the effectiveness of the Ibaraki BNCT beam shaping assembly to moderate a neutron beam suitable for BNCT at the proposed prototype Canadian compact accelerator-based neutron source (CANS) site, which uses a similar but slightly higher energy 10 MeV proton accelerator with a 1 mA average current. The advancements of CANSs in recent decades have enabled significant improvements in BNCT technologies, allowing it to become a more viable clinical treatment option. Key words: accelerator-based neutron production, boron neutron capture therapy (BNCT), cancer therapy, cancer, compact accelerator neutron source (CANS), 1. Historical progression of boron neutron capture therapy Boron neutron capture therapy (BNCT) is a radiotherapy used to treat and eliminate cancer by inducing a localized nuclear reaction inside the [...]

Encapsulation inside tiny unilamellar liposomes comprising distearoyl phosphatidylcholine/cholesterol and analysis for a function as boron-delivery agents for boron neutron capture therapy of cancer have been performed with the sodium salts of the apical-equatorial and the apical-apical isomer of (B20H17NH3)3-. Good tumor uptake and selectivity at extremely low injected doses of liposomal suspensions are evident in these isomers.